Alnylam partners with Inceptive in AI-driven RNAi drug discovery deal worth up to $2 billion

Alnylam Pharmaceuticals, Inc

Alnylam Pharmaceuticals, Inc

ALNY

0.00
  • Alnylam entered a strategic AI collaboration with Inceptive Nucleics to accelerate discovery of RNAi therapeutics under its Alnylam 2030 strategy.
  • Deal valued up to USD 2 billion; includes USD 30 million upfront consideration in cash and an Inceptive equity purchase.
  • Inceptive can earn additional payments tied to preclinical, regulatory, and commercial sales milestones.
  • Partnership integrates Inceptive generative foundation models with Alnylam’s siRNA data to improve candidate design, prioritization, potency, and efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260603131911) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.